Ameliorative effects of riboflavin on acetic acid-induced colonic injury in rats
Corresponding Author
Berna Karakoyun
Department of Basic Health Sciences, Faculty of Health Sciences, Marmara University, Istanbul, Turkey
Correspondence
Berna Karakoyun, PhD, Assoc. Professor, Department of Basic Health Sciences, Marmara University, Faculty of Health Sciences, Basibuyuk Yerleskesi, Maltepe, Istanbul, Turkey.
Email: [email protected]
Search for more papers by this authorBüşra Ertaş
Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey
Search for more papers by this authorMeral Yüksel
Department of Medical Laboratory, Vocational School of Health Related Professions, Marmara University, Istanbul, Turkey
Search for more papers by this authorDilek Akakın
Department of Histology and Embryology, School of Medicine, Marmara University, Istanbul, Turkey
Search for more papers by this authorÖzge Çevik
Department of Biochemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey
Search for more papers by this authorGöksel Şener
Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey
Search for more papers by this authorCorresponding Author
Berna Karakoyun
Department of Basic Health Sciences, Faculty of Health Sciences, Marmara University, Istanbul, Turkey
Correspondence
Berna Karakoyun, PhD, Assoc. Professor, Department of Basic Health Sciences, Marmara University, Faculty of Health Sciences, Basibuyuk Yerleskesi, Maltepe, Istanbul, Turkey.
Email: [email protected]
Search for more papers by this authorBüşra Ertaş
Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey
Search for more papers by this authorMeral Yüksel
Department of Medical Laboratory, Vocational School of Health Related Professions, Marmara University, Istanbul, Turkey
Search for more papers by this authorDilek Akakın
Department of Histology and Embryology, School of Medicine, Marmara University, Istanbul, Turkey
Search for more papers by this authorÖzge Çevik
Department of Biochemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey
Search for more papers by this authorGöksel Şener
Department of Pharmacology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey
Search for more papers by this authorSummary
Riboflavin (RF) has been found to be a promising antioxidant and/or anti-inflammatory agent in several studies. However, the effect of RF against acetic acid (AA)-induced colonic injury is currently unknown. This study aimed to investigate the potential antioxidant and protective effects of RF in a rat model of ulcerative colitis. Starting immediately after the colitis induction (AA+RF group) or 1 week before the colitis induction (RF+AA+RF group), the rats were treated with RF (25 mg/kg per day; p.o.) for 3 days. The control and AA groups received saline (1 mL; p.o.) whereas AA+SS group (positive control) received sulfasalazine (100 mg/kg per day; p.o.) for 3 days. Colonic samples were taken for the biochemical and histological assessments on the third day. High damage scores, elevated tissue wet weight index (WI), tissue myeloperoxidase (MPO) activity, 8-hydroxy-2′-deoxyguanosine levels and chemiluminescence values, and a pronounced decrease in antioxidant glutathione (GSH) levels of the AA group were all reversed by RF pretreatment (RF+AA+RF group) and SS treatment (AA+SS group) (P < .05-.001). Tissue WI, MPO activity and GSH levels were not statistically changed in the AA+RF group. Western blot analysis revealed that the decreased protein expressions of tissue collagen (COL) 1A1, COL3A1 and transforming growth factor-β1 in the AA group were elevated in all the treatment groups (P < .05-.001). In conclusion, RF exerts both the antioxidant and anti-inflammatory effects against AA-induced colonic inflammation by suppressing neutrophil accumulation, inhibiting reactive oxidant generation, preserving endogenous glutathione, improving oxidative DNA damage and regulating inflammatory mediators, suggesting a future potential role in the treatment and prevention of ulcerative colitis.
REFERENCES
- 1Shanahan F. Pathogenesis of ulcerative colitis. Lancet. 1993; 342: 407-411.
- 2Yadav V, Varum F, Bravo R, Furrer E, Bojic D, Basit AW. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Transl Res. 2016; 176: 38-68.
- 3Randhawa PK, Singh K, Singh N, Jaggi AS. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol. 2014; 18: 279-288.
- 4Pereira C, Grácio D, Teixeira JP, Magro F. Oxidative stress and DNA damage: implications in inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21: 2403-2417.
- 5Bitiren M, Karakilcik AZ, Zerin M, et al. Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. Biol Trace Elem Res. 2010; 136: 87-95.
- 6Işeri SO, Sener G, Sağlam B, Gedik N, Ercan F, Yeğen BC. Oxytocin ameliorates oxidative colonic inflammation by a neutrophil-dependent mechanism. Peptides. 2005; 26: 483-491.
- 7Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr. 2003; 77: 1352-1360.
- 8Northrop-Clewes CA, Thurnham DI. The discovery and characterization of riboflavin. Ann Nutr Metab. 2012; 61: 224-230.
- 9Massey V. The chemical and biological versatility of riboflavin. Biochem Soc Trans. 2000; 28: 283-296.
- 10Cumming RG, Mitchell P, Smith W. Diet and cataract: the Blue Mountains eye study. Ophthalmology. 2000; 107: 450-456.
- 11Alam MM, Iqbal S, Naseem I. Ameliorative effect of riboflavin on hyperglycemia, oxidative stress and DNA damage in type-2 diabetic mice: mechanistic and therapeutic strategies. Arch Biochem Biophys. 2015; 584: 10-19.
- 12Toyosawa T, Suzuki M, Kodama K, Araki S. Highly purified vitamin B2 presents a promising therapeutic strategy for sepsis and septic shock. Infect Immun. 2004; 72: 1820-1823.
- 13Hassan I, Chibber S, Naseem I. Ameliorative effect of riboflavin on the cisplatin induced nephrotoxicity and hepatotoxicity under photoillumination. Food Chem Toxicol. 2010; 48: 2052-2058.
- 14Al-Harbi NO, Imam F, Nadeem A, Al-Harbi MM, Iqbal M, Ahmad SF. Carbon tetrachloride-induced hepatotoxicity in rat is reversed by treatment with riboflavin. Int Immunopharmacol. 2014; 21: 383-388.
- 15Al-Harbi NO, Imam F, Nadeem A, et al. Riboflavin attenuates lipopolysaccharide-induced lung injury in rats. Toxicol Mech Methods. 2015; 25: 417-423.
- 16Iwanaga K, Hasegawa T, Hultquist DE, et al. Riboflavin-mediated reduction of oxidant injury, rejection and vasculopathy after cardiac allotransplantation. Transplantation. 2007; 83: 747-753.
- 17Yu Z, Morimoto K, Yu J, Bao W, Okita Y, Okada K. Endogenous superoxide dismutase activation by oral administration of riboflavin reduces abdominal aortic aneurysm formation in rats. J Vasc Surg. 2016; 64: 737-745.
- 18Levit R, de Giori GS, de Moreno de LeBlanc A, LeBlanc JG. Evaluation of the effect of soymilk fermented by a riboflavin-producing Lactobacillus plantarum strain in a murine model of colitis. Benef Microbes. 2017; 8: 65-72.
- 19Mazur-Bialy AI, Pochec E, Plytycz B. Immunomodulatory effect of riboflavin deficiency and enrichment-reversible pathological response versus silencing of inflammatory activation. J Physiol Pharmacol. 2015; 66: 793-802.
- 20Qureshi AA, Tan X, Reis JC, et al. Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids Health Dis. 2011; 10: 177.
- 21Pan Y, Liu Y, Guo H, et al. Associations between folate and vitamin B12 levels and inflammatory bowel disease: a meta-analysis. Nutrients. 2017; 9: E382.
- 22Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, Meldrum DR. Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol. 1999; 277: R922-R929.
- 23Weiss SJ, Ward PA. Immune complex induced generation of oxygen metabolites by human neutrophils. J Immunol. 1982; 129: 309-313.
- 24Hermaowicz A, Gibson PR, Jewell DP. The role of phagocytes in inflammatory bowel disease. Clin Sci. 1985; 69: 241-249.
- 25Bagchi D, Carryl OR, Tran MX, et al. Stress, diet and alcohol-induced oxidative gastrointestinal mucosal injury in rats and protection by bismuth subsalicylate. J Appl Toxicol. 1998; 18: 3-13.
10.1002/(SICI)1099-1263(199801/02)18:1<3::AID-JAT461>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 26Salvemini D, Riley DP, Lennon PJ, et al. Protective effects of a superoxide dismutase mimetic and peroxynitrite decomposition catalysts in endotoxin-induced intestinal damage. Br J Pharmacol. 1999; 127: 685-692.
- 27Ross D. Glutathione, free radicals and chemotherapeutic agents. Pharmacol Ther. 1988; 37: 231-249.
- 28Manthey KC, Rodriguez-Melendez R, Hoi JT, Zempleni J. Riboflavin deficiency causes protein and DNA damage in HepG2 cells, triggering arrest in G1 phase of the cell cycle. J Nutr Biochem. 2006; 17: 250-256.
- 29Ibrahim RY, Hassan AI, Al-Adham EK. The anti-ulcerative colitis effects of Annona squamosa Linn. leaf aqueous extract in experimental animal model. Int J Clin Exp Med. 2015; 8: 21861-21870.
- 30Halliwell B, Aruoma OI. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett. 1991; 281: 9-19.
- 31D'Inca R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis. 2004; 10: 23-27.
- 32Suzuki S, Tajima T, Sassa S, Kudo H, Okayasu I, Sakamoto S. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice. Anticancer Res. 2006; 26: 4223-4228.
- 33von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000; 47: 63-73.
- 34De Bruyn JR, Meijer SL, Wildenberg ME, Bemelman WA, van den Brink GR, D'Haens GR. Development of fibrosis in acute and longstanding ulcerative colitis. J Crohns Colitis. 2015; 9: 966-972.
- 35Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol. 2000; 67: 149-159.
- 36Louis E. The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha. Acta Gastroenterol Belg. 2001; 64: 1-5.
- 37Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987; 6: 1899-1904.
- 38Verrecchia F, Mauviel A. Transforming growth factor-beta signalling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002; 118: 211-215.
- 39Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol. 2017; 52: 777-787.
- 40Hahm KB, Im YH, Parks TW, et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut. 2001; 49: 190-198.
- 41Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001; 108: 601-609.
- 42Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappaB/RelA. Genes Dev. 2000; 14: 187-197.
- 43Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 1999; 397: 710-713.
- 44Singh UP, Singh NP, Murphy EA, et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016; 77: 44-49.
- 45Huang YF, Zhou JT, Qu C, et al. Anti-inflammatory effects of Brucea javanica oil emulsion by suppressing NF-κB activation on dextran sulfate sodium-induced ulcerative colitis in mice. J Ethnopharmacol. 2017; 198: 389-398.
- 46MacPherson B, Pfeiffer C. Experimental production of diffuse colitis in rats. Digestion. 1978; 17: 135-150.
- 47Seishima R, Okabayashi K, Nagano O, et al. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9+ cancer stem cells in ulcerative colitis-related cancer. Clin Res Hepatol Gastroenterol. 2016; 40: 487-493.
- 48McCafferty DM, Sharkey KA, Wallace JL. Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol. 1994; 266: G560-G567.
- 49Gué M, Bonbonne C, Fioramonti J, et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am J Physiol. 1997; 272: G84-G91.
- 50Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982; 78: 206-209.
- 51Hillegass LM, Griswold DE, Brickson B, Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods. 1990; 24: 285-295.
- 52Davies GR, Simmonds NJ, Stevens TRJ, Grandison A, Blake DR, Rampton DS. Mucosal reactive oxygen metabolite production in duodenal ulcer disease. Gut. 1992; 33: 1467-1472.
- 53Aykaç G, Uysal M, Yalcin AS, Koçak-Toker N, Sivas A, Öz H. The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione, glutathione peroxidase and glutathione transferase in rats. Toxicology. 1985; 36: 71-76.
- 54Cevik O, Adiguzel Z, Baykal AT, Somay G, Sener A. The apoptotic actions of platelets in acute ischemic stroke. Mol Biol Rep. 2013; 40: 6721-6727.